Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Up 60.8% in January

Kalaris Therapeutics Inc. (NASDAQ:KLRS) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 867,767 shares, an increase of 60.8% from the December 31st total of 539,567 shares. Approximately 18.6% of the shares of the company are sold short. Based on an average daily trading volume, of 100,271 shares, the days-to-cover ratio is presently 8.7 days. Based on an average daily trading volume, of 100,271 shares, the days-to-cover ratio is presently 8.7 days. Approximately 18.6% of the shares of the company are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP bought a new position in Kalaris Therapeutics during the 3rd quarter valued at approximately $1,394,000. Belpointe Asset Management LLC bought a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at $231,000. Fortis Capital Advisors LLC bought a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $231,000. XTX Topco Ltd bought a new position in Kalaris Therapeutics in the 2nd quarter worth $65,000. Finally, Bridgeway Capital Management LLC bought a new position in Kalaris Therapeutics in the 3rd quarter worth approximately $130,000. 66.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on KLRS shares. Citizens Jmp began coverage on shares of Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price target for the company. Wall Street Zen cut shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Finally, Chardan Capital started coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Kalaris Therapeutics Stock Performance

NASDAQ KLRS traded down $0.01 during trading on Monday, hitting $8.87. 3,338 shares of the company’s stock traded hands, compared to its average volume of 73,170. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $12.90. The business has a 50 day moving average of $8.42 and a 200-day moving average of $5.74. The stock has a market capitalization of $165.87 million, a price-to-earnings ratio of -2.35 and a beta of -0.09.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.